These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 26981887

  • 1. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Lei J, Zhong J, Hao J, Liu Z, Zhang P, Wu L, Yan L, Zhu J, Zeng Y, Li B, Wen T, Wang W.
    Oncotarget; 2016 Jul 05; 7(27):42598-42607. PubMed ID: 26981887
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P.
    World J Gastroenterol; 2016 Jun 21; 22(23):5384-92. PubMed ID: 27340354
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM, STORM investigators.
    Lancet Oncol; 2015 Oct 21; 16(13):1344-54. PubMed ID: 26361969
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
    Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Wu Q, Zhang T, Kong D, Li Q, Song T.
    Med Oncol; 2015 Apr 21; 32(4):107. PubMed ID: 25750040
    [Abstract] [Full Text] [Related]

  • 7. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH.
    Clin Mol Hepatol; 2016 Mar 21; 22(1):160-7. PubMed ID: 27044767
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ, Kim SS, Nam JS, Oh MJ, Kang DR, Kim JK, Lee JH, Kim B, Yang MJ, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW, Cheong JY.
    Cytokine; 2017 Jul 21; 95():118-125. PubMed ID: 28260649
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
    Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q.
    Liver Int; 2015 Sep 21; 35(9):2147-54. PubMed ID: 25676812
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
    Li J, Hou Y, Cai XB, Liu B.
    World J Gastroenterol; 2016 Apr 21; 22(15):4034-40. PubMed ID: 27099447
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L, Fuks D, Pessaux P, Muscari F, Le Treut YP, Faivre S, Belghiti J.
    Ann Surg Oncol; 2013 Oct 21; 20(11):3603-9. PubMed ID: 23715965
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND, Marshall VD, Singal AG, Nathan H, Lok AS, Balkrishnan R, Shahinian V.
    Hepatology; 2017 Jan 21; 65(1):122-133. PubMed ID: 27770556
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.
    Antoniou EA, Margonis GA, Amini N, Anastasiou M, Angelou A, Kim Y, Kouraklis G.
    J BUON; 2016 Jan 21; 21(5):1189-1194. PubMed ID: 27837622
    [Abstract] [Full Text] [Related]

  • 20. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Waki K, Tsuji K, Kohno H, Kohno H, Moriya T, Chayama K.
    J Dig Dis; 2015 Sep 21; 16(9):505-12. PubMed ID: 26121102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.